While approximately half of lung adenocarcinomas harbor actionable oncogenic mutations, with targeted therapies available for EGFR (exon 19 deletions, exon 20 insertion, and L858R point mutations), KRAS-G12C, BRAF, MET, HER2, ALK, ROS1, RET, and NTRK alterations (80), the remaining half and nearly all squamous cell lung cancers lack identifiable oncogenic driver alterations, leaving them mostly without precision-targeted treatment options. Here, KRAS is linked to lung adenocarcinoma.